AMW GmbH is located in Warngau, Upper Bavaria, approximately 40 km southeast of Munich, close to the Alps.
The company possesses all of the necessary regulatory licenses for the commercial manufacturing of transdermal systems and biodegradable implants. Additionally, AMW is a licensed to train commercial and chemical apprentices.
Our ambition is to serve patients, physicians and nursing staff with optimal performance and the highest possible safety.
A team of excellent, highly educated and motivated scientists and technicians within the company works together with the clients' experts, or other external experts, to provide the best possible solutions.
In cooperation with our partners, we define the most efficient development schedule, and update it as necessary. We agree upon fixed budgets so that the development risk remains at the lowest possible levels. Furthermore, we invest in R&D with our own projects and license them to customers. Production is carried out completely at AMW.
We draw our motivation from the success of our work and from the benefits it provides patients, while aiming at balanced growth.
Flat hierarchies, clear structures, common goals and exceptional team spirit is AMW’s success formula.
A profit-sharing model for employees was already envisaged during the founding of the company.
These measures were complimented with flexible working schedules, encouragement of families and promotion of the personal and professional development of each employee. Additionally, we have a training rate of about 20%. We believe that a leading position can only be achieved and improved through an active culture of lifelong learning.
Dr. Wilfried Fischer founded the AMW GmbH in 2008 and is managing director and head of development.
After his pharmaceutical studies in Braunschweig and the successful completion of his doctorate in pharmaceutical technology at the University of Münster,
he took on senior positions in the development department of diverse leading pharmaceutical companies.
His last position was as head of development for a leading global generic pharmaceuticals company.
In 1997 he founded the Novosis Agin in Munich, which because of its rapid growth,
moved to a new plant in Miesbach in 2000. During this period and up until the sale of the company in 2008,
Dr. Fischer developed Novosis Agin with its 150 employees
In 2018 Dr. Friedrich Tegel was appointed managing director operations and 2019 Philipp Karbach was appointed managing director comercial.
Important partners from industry, consultancies, venture capital as well as private persons have accompanied AMW GmbH for many years and remain closely involved beyond the underlying collaboration